|
ホシノ ジユンイチ
HOSHINO Junichi
星野 純一 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | がん薬物療法時の腎障害診療ガイドライン2022(第4章) がんサバイバーのCKD治療(Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022) |
| 掲載誌名 | 正式名：International Journal of Clinical Oncology 略 称：Int J Clin Oncol ISSNコード：14377772/13419625 |
| 掲載区分 | 国外 |
| 出版社 | シュプリンガー・ジャパン(株) |
| 巻・号・頁 | 28(10),pp.1333-1342 |
| 著者・共著者 | Ishikura Kenji, Omae Kenji, Sasaki Sho, Shibagaki Yugo, Ichioka Satoko, Okuda Yusuke, Koitabashi Kenichiro, Suyama Koichi, Mizukami Takuro, Kondoh Chihiro, Hirata Sumio, Matsubara Takeshi, Hoshino Junichi, Yanagita Motoko |
| 発行年月 | 2023/10/28 |
| 概要 | Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible. |
| DOI | 10.1007/s10147-023-02375-1 |
| 文献番号 | XA19140005<Pre 医中誌> |
| PMID | 37418141 |